Sugi Predict

Sugi Predict / Targets / GRPR

GRPR

Gastrin-releasing peptide receptor · P30550 · GRPR on Sugi Atlas →

4,035 patent compounds predicted against GRPR, 2,768 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2292312 SCHEMBL2292312 0.90 20/20
SCHEMBL2292367 SCHEMBL2292367 0.90 20/20
SCHEMBL1251393 SCHEMBL1251393 0.89 20/20
SCHEMBL1251420 SCHEMBL1251420 0.89 20/20
SCHEMBL1251567 SCHEMBL1251567 0.89 20/20
SCHEMBL1251587 SCHEMBL1251587 0.89 20/20
SCHEMBL1251635 SCHEMBL1251635 0.89 20/20
SCHEMBL1392465 SCHEMBL1392465 0.89 20/20
SCHEMBL1526993 SCHEMBL1526993 0.89 20/20
SCHEMBL1251302 SCHEMBL1251302 0.87 20/20
SCHEMBL1618983 SCHEMBL1618983 0.87 20/20
SCHEMBL1252165 SCHEMBL1252165 0.87 20/20
SCHEMBL1393352 SCHEMBL1393352 0.87 20/20
SCHEMBL1251619 SCHEMBL1251619 0.87 20/20
SCHEMBL1251596 SCHEMBL1251596 0.86 20/20
SCHEMBL1252671 SCHEMBL1252671 0.86 20/20
SCHEMBL1392489 SCHEMBL1392489 0.86 20/20
SCHEMBL1618993 SCHEMBL1618993 0.86 20/20
SCHEMBL1250067 SCHEMBL1250067 0.86 20/20
SCHEMBL1252293 SCHEMBL1252293 0.86 20/20

Clinical trials — most relevant to GRPR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET PHASE2/PHASE3COMPLETED
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET PHASE2/PHASE3COMPLETED
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks PHASE2COMPLETED
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer PHASE1/PHASE2RECRUITING
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. PHASE1/PHASE2ACTIVE_NOT_RECRUITING
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer PHASE1/PHASE2COMPLETED
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT PHASE1/PHASE2COMPLETED
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy PHASE1/PHASE2RECRUITING
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake PHASE1/PHASE2COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors PHASE1RECRUITING
68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study PHASE1UNKNOWN
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients PHASE1UNKNOWN
68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients PHASE1UNKNOWN
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors PHASE1RECRUITING
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC PHASE1COMPLETED
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. PHASE1ACTIVE_NOT_RECRUITING
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas EARLY_PHASE1UNKNOWN
68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients EARLY_PHASE1UNKNOWN
68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor EARLY_PHASE1UNKNOWN
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer EARLY_PHASE1RECRUITING
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer nanUNKNOWN
Dietary Carbohydrate and GERD in Veterans nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Gastrin, Anti-helicobacter Pylori and Pepsinogen Diagnostic Accuracy Study nanNOT_YET_RECRUITING
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) nanNOT_YET_RECRUITING
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine nanCOMPLETED
Gastrointestinal Hormonal Regulation of Obesity nanCOMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GRPR binder may also engage these)

ProteinNameSimilarity
P52500 — 1.000 P52500 →
P21729 — 0.999 P21729 →
P24053 — 0.990 P24053 →
O54799 — 0.990 O54799 →
NMBR Neuromedin-B receptor 0.988 landscape →
B2ZI34 — 0.987 B2ZI34 →
Q61614 — 0.973 Q61614 →
P21450 — 0.971 P21450 →
Q5KSU9 — 0.971 Q5KSU9 →
EDNRA Endothelin-1 receptor 0.968 landscape →
Q95L55 — 0.968 Q95L55 →
P26684 — 0.965 P26684 →
Q29010 — 0.959 Q29010 →
GHSR Growth hormone secretagogue receptor type 1 0.955 landscape →
P42866 — 0.955 P42866 →
Q5IS39 — 0.955 Q5IS39 →
P79350 — 0.955 P79350 →
O62709 — 0.954 O62709 →
Q61212 — 0.954 Q61212 →
Q95247 — 0.952 Q95247 →
P21451 — 0.952 P21451 →
P33534 — 0.951 P33534 →
A5A4K9 — 0.951 A5A4K9 →
P47751 — 0.951 P47751 →
Q9WVD0 — 0.951 Q9WVD0 →
P33535 — 0.950 P33535 →
Q9MYW9 — 0.950 Q9MYW9 →
P34975 — 0.950 P34975 →
O08725 — 0.950 O08725 →
Q5IS84 — 0.949 Q5IS84 →